Loading clinical trials...
Loading clinical trials...
It is an open label observation clinical trial, all participants are liver transplant patients. The investigators deem to make a better criteria for assessing liver fibrosis after liver transplantation. The point of the clinical trial is to evaluate the efficacy of multiparameter MRI in the diagnosis of liver fibrosis after liver transplantation.
We collected patients aged 18 to 85 who had undergone liver transplantation. At the same time, all patients underwent liver biopsy or ultrasonic transient elastography after MRI. People who were allergic to gadolinium contrast agent, serious cardiopulmonary disease and contraindications to MRI were excluded.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
No
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Start Date
March 18, 2022
Primary Completion Date
December 1, 2022
Completion Date
December 1, 2022
Last Updated
March 23, 2022
40
ESTIMATED participants
Gadopentetate Dimeglumine Injection
DIAGNOSTIC_TEST
Lead Sponsor
The Affiliated Hospital of Qingdao University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions